-
Mashup Score: 10
An abstract is unavailable.
Source: journals.lww.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 2
An abstract is unavailable.
Source: journals.lww.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
For patients with locally advanced #rectalcancer, disease-free survival at 5 years was 78.6% for patients who received preoperative #chemoradiation and 80.8% for patients who received preoperative #chemotherapy with selective radiation: https://t.co/MIQzAnC6IX #CancerResearch https://t.co/oPAlo6kXHj
-
-
Mashup Score: 0PRO Analysis of PROSPECT Trial Reveals Distinct Toxicity Profiles With FOLFOX vs Chemoradiation in Rectal Cancer - 10 month(s) ago
FOLFOX was associated with lower rates or diarrhea and bowel dysfunction, but higher rates of fatigue, anxiety, nausea, and neuropathy, in data from the phase 2/3 PROSPECT trial.
Source: Oncology Nursing NewsCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
FOLFOX was associated with lower rates or diarrhea and bowel dysfunction, but higher rates of fatigue, anxiety, nausea, and neuropathy, in data from the phase 2/3 PROSPECT trial. #oncology #rectalcancer #chemoradiation #chemotherapy @UNC_Lineberger https://t.co/Ofe15WUDK3
-
-
Mashup Score: 1PRO Analysis of PROSPECT Trial Reveals Distinct Toxicity Profiles With FOLFOX vs Chemoradiation in Rectal Cancer - 10 month(s) ago
FOLFOX was associated with lower rates or diarrhea and bowel dysfunction, but higher rates of fatigue, anxiety, nausea, and neuropathy, in data from the phase 2/3 PROSPECT trial.
Source: Oncology Nursing NewsCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
FOLFOX was associated with lower rates or diarrhea and bowel dysfunction, but higher rates of fatigue, anxiety, nausea, and neuropathy, in data from the phase 2/3 PROSPECT trial. #oncology #rectalcancer #chemoradiation #chemotherapy @UNC_Lineberger https://t.co/1JGe2dXk8V
-
-
Mashup Score: 0PRO Analysis of PROSPECT Trial Reveals Distinct Toxicity Profiles With FOLFOX vs Chemoradiation in Rectal Cancer - 10 month(s) ago
FOLFOX was associated with lower rates or diarrhea and bowel dysfunction, but higher rates of fatigue, anxiety, nausea, and neuropathy, in data from the phase 2/3 PROSPECT trial.
Source: Oncology Nursing NewsCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
PRO Analysis of PROSPECT Trial Reveals Distinct Toxicity Profiles With FOLFOX vs Chemoradiation in Rectal Cancer #oncology #nursing #rectalcancer #chemoradiation #chemotherapy https://t.co/gvB6Cdc93T
-
-
Mashup Score: 1FOLFOX Demonstrates Comparable Efficacy to Chemoradiation for Neoadjuvant Treatment of Locally Advanced Rectal Cancer - 11 month(s) ago
Preoperative FOLFOX demonstrated noninferior efficacy outcomes vs preoperative chemoradiation in locally advanced rectal cancer.
Source: Oncology Nursing NewsCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Preoperative FOLFOX demonstrated noninferior efficacy outcomes vs preoperative chemoradiation in locally advanced rectal cancer. #oncology #Nursing #ASCO23 #chemoradiation https://t.co/iuZrrdUZZs https://t.co/2qz6P5RMjf
-
-
Mashup Score: 1FOLFOX Demonstrates Comparable Efficacy to Chemoradiation for Neoadjuvant Treatment of Locally Advanced Rectal Cancer - 11 month(s) ago
Preoperative FOLFOX demonstrated noninferior efficacy outcomes vs preoperative chemoradiation in locally advanced rectal cancer.
Source: Oncology Nursing NewsCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
FOLFOX Demonstrates Comparable Efficacy to Chemoradiation for Neoadjuvant Treatment of Locally Advanced Rectal Cancer #oncology #Nursing #ASCO23 #chemoradiation https://t.co/8NQ9UqpBhJ
-
-
Mashup Score: 1Please wait whilst we redirect you - 11 month(s) ago
About ScienceDirectRemote accessShopping cartAdvertiseContact and supportTerms and conditionsPrivacy policyWe use cookies to help provide and enhance our service and tailor content and ads. By continuing you agree to the use of cookies.Copyright © 2023 Elsevier B.V. or its licensors or contributors. ScienceDirect® is a registered trademark of Elsevier B.V.ScienceDirect® is a registered trademark…
Source: www.sciencedirect.comCategories: Hem/Oncs, Latest HeadlinesTweet-
Our latest meta-analysis on #chemoradiation in nasopharyngeal cancer out in @TheLancetOncol Huge collaborative work. ✅ 28 trials, 8.000+ pts, 7.6y FU ✅ more chemo (ind+conc or conc+adj) ➡️superior (OS/PFS) to CRT alone but more tox Free 50day link: https://t.co/BtRJDZERRZ https://t.co/v2v5MsinnV
-
-
Mashup Score: 1
At the SGO Annual Meeting on Women’s Cancer, Jyoti Mayadev, MD, discusses best practices for treating patients with IB3 cervical cancer, focusing on the benefits of chemoradiation treatment.
Source: HMP Global Learning NetworkCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
At the 2023 Society of Gynecological Oncology’s Annual Meeting on Women’s Cancer, Jyoti Mayadev, MD, discussed best practices for treating patients with IB3 #CervicalCancer, focusing on #chemoradiation treatment. Learn more: https://t.co/Pysr6w7cnZ @SGO_org https://t.co/V4Bllsh2gC
-
-
Mashup Score: 0
Bladder-sparing strategy delivers ‘encouraging’ control with few grade III toxicities
Source: www.medpagetoday.comCategories: General Medicine News, Latest HeadlinesTweet-
Do the results mean that more #elderly, frail patients than previously realized could be good candidates for #chemoradiation? #Bladder #oncology @ASCO #ASCOReadingRoom Read more: https://t.co/sTkKtQ4GqC https://t.co/k7yO2YtOQs
-
A small study of stage II to III mismatch repair (MMR)-deficient #rectalcancer showed preoperative #immunotherapy led to a 100% clinical complete response rate without the use of #chemoradiation or surgery. https://t.co/sXhP4Srzma https://t.co/JJ4G5MIPcw